| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/28/2002 | EP1233959A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 08/28/2002 | EP1233951A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 08/28/2002 | EP1233950A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS |
| 08/28/2002 | EP1233948A1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 08/28/2002 | EP1233943A2 Ionizable indolinone derivatives and their use as ptk ligands |
| 08/28/2002 | EP1233815A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 08/28/2002 | EP1233811A2 Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use |
| 08/28/2002 | EP1233789A2 Prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| 08/28/2002 | EP1233786A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 08/28/2002 | EP1233781A1 Assays and therapies for latent viral infection |
| 08/28/2002 | EP1233778A1 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 08/28/2002 | EP1233777A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1233776A1 Urotensin-ii cyclic analogs |
| 08/28/2002 | EP1233774A1 Urotensin-ii analogs |
| 08/28/2002 | EP1233770A2 Phosphonate compounds |
| 08/28/2002 | EP1233769A1 Novel compounds |
| 08/28/2002 | EP1233768A1 Carvedilol methanesulfonate |
| 08/28/2002 | EP1233767A1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 08/28/2002 | EP1233756A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 08/28/2002 | EP1140898B1 Amide and urea derivatives as 5-ht reuptake inhibitors and as 5-ht1b/1d ligands |
| 08/28/2002 | EP1071702B1 Fatty acid derivatives of bile acids and bile acid derivatives |
| 08/28/2002 | EP1005347A4 Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases |
| 08/28/2002 | EP0973731B1 Hydroxamic acid derivatives |
| 08/28/2002 | EP0933995A4 Method of treating endothelial injury |
| 08/28/2002 | EP0928191B1 Pharmaceutical compositions comprising s-alkylisothiouronium derivatives |
| 08/28/2002 | EP0918777B1 SELECTED DERIVATIVES OF K-252a |
| 08/28/2002 | EP0918759B1 Novel thiazolidone-2 derivatives, 4-diketone substituted, method for obtaining them and pharmaceutical compositions containing same |
| 08/28/2002 | EP0892804B1 Isoxazolidine derivatives |
| 08/28/2002 | EP0877626B1 Anti-cd18 antibodies for use against stroke |
| 08/28/2002 | CN1366524A Sulfonamide derivative as matrix metalloproteinase inhibitor |
| 08/28/2002 | CN1366521A Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators |
| 08/28/2002 | CN1366520A Medicine |
| 08/28/2002 | CN1366518A Biphenyl butyric acid derivative as matrix metalloproteinase inhibitor |
| 08/28/2002 | CN1366461A Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as active ingredient |
| 08/28/2002 | CN1366182A Method for screening cardiovascular disease resistant medicine by ELISA screening system with ApoAI cell target |
| 08/28/2002 | CN1365976A Process for extracting medicinal component from pueraria root |
| 08/28/2002 | CN1365973A New cycloheplene compound, its preparation method and medicine composition containing same |
| 08/28/2002 | CN1365819A Medicine for treating apoplexy |
| 08/28/2002 | CN1365816A Health-care medicine containing ganoderic oligose for preventing and treating cardiovascular disease and its preparing process |
| 08/28/2002 | CN1365815A Orally applied capsule 'Yejuzhi' |
| 08/28/2002 | CN1365793A Nano medicine 'Xueyaping' and its preparing process |
| 08/28/2002 | CN1365760A Nano medicine 'Zhuli Datan' and its preparing process |
| 08/28/2002 | CN1365753A Nano medicine 'Yanghe Jiening' and its preparing process |
| 08/28/2002 | CN1365739A Nano medicine 'Guanxin Shengmai' for treating coronary heart disease and its preparing process |
| 08/28/2002 | CN1365736A Nano medicine for treating coronary heart disease and its preparing process |
| 08/28/2002 | CN1365720A Nano 25-component pearl medicine and its preparing process |
| 08/28/2002 | CN1365694A Nano medicine 'Huitian Zaizao' and its preparing process |
| 08/28/2002 | CN1365693A Nano medicine for treating cervical cancer and its preparing process |
| 08/28/2002 | CN1365678A Nano medicine 'Yixintong' and its preparing process |
| 08/28/2002 | CN1365665A Synergistic composition containing ascobic acid salt and lysine used for diseases related with extracellular substrate degeneration |
| 08/28/2002 | CN1365664A Medicine for removing vegetation from human body and its preparing process and application |
| 08/28/2002 | CN1089764C Substituted heterocyclic compounds, preparation method thereof and pharmaceutical compositions containing same |
| 08/28/2002 | CN1089586C (5-androstene-17-one-3 beta hydroxyl) diacid ester, and its pharmaceutical use |
| 08/28/2002 | CN1089584C Treatment for arteriosclerosis and vitiligoidea |
| 08/28/2002 | CA2401557A1 Medecine for improving retinal functions |
| 08/27/2002 | US6441193 Intermediates such as 1-(2-(4-(6-methoxy-3,4-dihydronaphtha-len-1-yl)phenoxy)ethyl)pyrrolidine and compounds such as cis-6-phenyl-5-(4-(2-pyrrolidin-1-ylethoxy)phenyl)-5,6,7,8 -tetrahydronaphthalen-2-ol, hydrobromide salt |
| 08/27/2002 | US6441177 (4-bromo-phenyl)-(4-(6-(cyclopropyl-methyl-amino)-hexyloxy)-2-fluoro -phenyl)-methanone; antimycotic and cholesterol lowering activity |
| 08/27/2002 | US6441176 Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
| 08/27/2002 | US6441137 Tie-2 ligands; tie= ?tyrosine kinase with ig (immunoglobulins) and egf (epidermal growth factor) homology domains?; tumor neovascularization |
| 08/27/2002 | US6441049 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 08/27/2002 | US6441048 Methods of treating affective disorders using derivatives of (-)-venlafaxine |
| 08/27/2002 | US6441036 Treating atherosclerosis and insulin resistance |
| 08/27/2002 | US6441017 Inhibitors of prenyl-protein transferase |
| 08/27/2002 | US6441015 Tetrazole compounds as thyroid receptor ligands |
| 08/27/2002 | US6441012 Chemical compounds |
| 08/27/2002 | US6441010 Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them |
| 08/27/2002 | US6441008 Benzamide derivatives as thrombin inhibitors |
| 08/27/2002 | US6441004 Monocyte chemoattractant protein-1 inhibitor compounds |
| 08/27/2002 | US6441000 Compounds useful in therapy |
| 08/27/2002 | US6440995 Quinolin-4-yl derivatives |
| 08/27/2002 | US6440991 Ethers of 7-desmethlrapamycin |
| 08/27/2002 | US6440976 Iminopyrimidine NMDA NR2B receptor antagonists |
| 08/27/2002 | US6440975 Amino acid derivatives, the preparation and use thereof as endothelin antagonists |
| 08/27/2002 | US6440973 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
| 08/27/2002 | US6440972 Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
| 08/27/2002 | US6440968 Use of maduraohtalazine derivatives as inhibitors of proinflammatory cytokines |
| 08/27/2002 | US6440966 Benzenesulfonamide derivatives and their use as MEK inhibitors |
| 08/27/2002 | US6440962 Cardiovascular disorders, antiischemic agents |
| 08/27/2002 | US6440958 Acrylic and propionic acid compounds, intermediates, processes, compositions, and methods |
| 08/27/2002 | US6440955 Anti-inflammatory agents |
| 08/27/2002 | US6440948 Thiophene A2A receptor agonists |
| 08/27/2002 | US6440947 Coadministration of an adenosine a2 receptor agonist, e.g., adenosine and heparin or heparin-like compound to improve collateral coronary circulation in patients suffering from myocardial infarction; angiogenisis |
| 08/27/2002 | US6440736 Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules |
| 08/27/2002 | US6440468 Method for obtaining apolar and polar extracts of curcuma and applications thereof |
| 08/27/2002 | CA2173939C Oligopeptides derived from c-reactive protein fragments |
| 08/27/2002 | CA2167039C Alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them |
| 08/27/2002 | CA2125888C Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
| 08/27/2002 | CA2104795C 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders |
| 08/27/2002 | CA2062837C 8-substituted purines as selective adenosine receptor agents |
| 08/27/2002 | CA2032311C 2,19-methyleneoxy and 2,19-methylenethio bridged steroids as aromatase and 19-hydroxylase inhibitors |
| 08/22/2002 | WO2002064793A2 G protein-coupled receptor-like proteins and nucleics acids encoding same |
| 08/22/2002 | WO2002064792A2 Molecules for disease detection and treatment |
| 08/22/2002 | WO2002064791A2 Proteins and nucleic acids encoding same |
| 08/22/2002 | WO2002064772A1 Human nmda receptor splice variant |
| 08/22/2002 | WO2002064755A2 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | WO2002064748A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | WO2002064627A2 Crystallization of igf-1 |
| 08/22/2002 | WO2002064626A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/22/2002 | WO2002064621A2 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
| 08/22/2002 | WO2002064616A2 Agonists and antagonists of sphingosine-1-phosphate receptors |